Mometasone furoate (Asmanex Twisthaler
) is available as a DPI with 220 micrograms/actuation dosing.
-- The Food and Drug Administration has approved Schering-Plough Corp.'s Asmanex Twisthaler
for treating asthma in ages 4 to 11.
(mometasone furoate inhalation powder, Schering-Plough Corp.) The Food and Drug Administration approved Asmanex Twisthaler
for once-daily maintenance treatment of asthma in children aged 4-11 years.
The Asmanex Twisthaler
is not indicated for treatment of acute asthma episodes.
Some DPIs, such as AstraZeneca's Turbohaler design or the Asmanex Twisthaler
, contain a reservoir of powder containing the active ingredient.
The FDA approved Asmanex Twisthaler
220 mcg (mometasone furoate inhalation powder) for first-line maintenance treatment of asthma as preventive therapy in patients aged 12 years and older.